Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2023

Open Access 01-12-2023 | Bronchiectasis | Research

A case-control study on the risk factors associated with the occurrence of non-tuberculous mycobacteria pulmonary disease in bronchiectasis patients

Authors: Yinping Feng, Jing Guo, Shuirong Luo, Zunjing Zhang

Published in: BMC Pulmonary Medicine | Issue 1/2023

Login to get access

Abstract

Objective

The objective of this study is to analyze the risk factors associated with bronchiectasis combined with non-tuberculous mycobacteria pulmonary disease(NTM-PD) and provide a basis for more effective prevention and treatment strategies.

Methods

The study subjects for this manuscript were patients with bronchiectasis who were admitted to the infection department between January 2021 and June 2023.There were 34 patients with NTM-PD in the observation group, and 52 patients with simple bronchiectasis in the control group. Basic information, imaging features, serum albumin levels, and infection indicators were collected from both groups of patients.Univariate and multivariate logistic regression analysis were performed to analyze the risk factors for NTM-PD in patients with bronchiectasis.

Results

Multivariate logistic regression analysis revealed that bronchiectasis exacerbation occurring at least twice a year(OR = 3.884, 95% CI: 1.200-12.568), involvement of three or more lung lobes with bronchiectasis (OR = 3.932, 95% CI: 1.208–12.800), hypoalbuminemia (OR = 3.221, 95% CI: 1.015–10.219), and the NLR index (OR = 1.595, 95% CI: 1.200-2.119) were significant risk factors for non-tuberculous mycobacteria pulmonary disease in individuals with bronchiectasis (P < 0.05).

Conclusion

Patients with bronchiectasis accompanied by NTM-PD present specific risk factors that should be promptly addressed through prevention and treatment.
Literature
1.
go back to reference Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.CrossRefPubMed Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.CrossRefPubMed
2.
go back to reference Chandrasekaran R, Mac Aogáin M, Chalmers JD, et al. Geographic variation in the aetiologyepidemiology and microbiology of bronchiectasis. BMC Pulm Med. 2018 May;22(1):83. Chandrasekaran R, Mac Aogáin M, Chalmers JD, et al. Geographic variation in the aetiologyepidemiology and microbiology of bronchiectasis. BMC Pulm Med. 2018 May;22(1):83.
3.
go back to reference Brode SK, Daley CL, Marras TK. The epidemiologic relationship between Tuberculosis and non-tuberculous mycobacterial Disease: a systematic review. Int J Tuberc Lung Dis. 2014;18(11):1370–7.CrossRefPubMed Brode SK, Daley CL, Marras TK. The epidemiologic relationship between Tuberculosis and non-tuberculous mycobacterial Disease: a systematic review. Int J Tuberc Lung Dis. 2014;18(11):1370–7.CrossRefPubMed
4.
go back to reference Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary Disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1–ii64.CrossRefPubMed Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary Disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1–ii64.CrossRefPubMed
5.
go back to reference Hill AT, Sullivan AL, Chalmers JD, et al. British thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1–69.CrossRefPubMed Hill AT, Sullivan AL, Chalmers JD, et al. British thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1–69.CrossRefPubMed
6.
go back to reference Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis. 2017;14(4):377–84.CrossRefPubMedPubMedCentral Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis. 2017;14(4):377–84.CrossRefPubMedPubMedCentral
7.
go back to reference Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47(1):186–93.CrossRefPubMed Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47(1):186–93.CrossRefPubMed
8.
go back to reference Duff RM, Simmonds NJ, Davies JC, et al. A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis. Eur Respir J. 2013;41(4):991–3.CrossRefPubMed Duff RM, Simmonds NJ, Davies JC, et al. A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis. Eur Respir J. 2013;41(4):991–3.CrossRefPubMed
9.
go back to reference Máiz L, Girón R, Olveira C, et al. Prevalence and factors associated with nontuberculous mycobacteria in non-cystic fibrosis bronchiectasis: a multicenter observational study. BMC Infect Dis. 2016;16:437.CrossRefPubMedPubMedCentral Máiz L, Girón R, Olveira C, et al. Prevalence and factors associated with nontuberculous mycobacteria in non-cystic fibrosis bronchiectasis: a multicenter observational study. BMC Infect Dis. 2016;16:437.CrossRefPubMedPubMedCentral
10.
go back to reference Shteinberg M, Stein N, Adir Y et al. Prevalence, risk factors and prognosis of nontuberculous mycobacterial Infection among people with bronchiectasis: a population survey. Eur Respir J 2018;51. Shteinberg M, Stein N, Adir Y et al. Prevalence, risk factors and prognosis of nontuberculous mycobacterial Infection among people with bronchiectasis: a population survey. Eur Respir J 2018;51.
12.
go back to reference Chen ZG, Li YY, Wang ZN, et al. Aberrant epithelial remodeling with impairment of cilia architecture in non-cystic fibrosis bronchiectasis. J Thorac Dis. 2018;10(3):1753–64.CrossRefPubMedPubMedCentral Chen ZG, Li YY, Wang ZN, et al. Aberrant epithelial remodeling with impairment of cilia architecture in non-cystic fibrosis bronchiectasis. J Thorac Dis. 2018;10(3):1753–64.CrossRefPubMedPubMedCentral
13.
go back to reference Bai X, Bai A, Honda JR, et al. Alpha-1-Antitrypsin enhances primary human macrophage immunity against non-tuberculous mycobacteria. Front Immunol. 2019 Jun;26:10:1417. Bai X, Bai A, Honda JR, et al. Alpha-1-Antitrypsin enhances primary human macrophage immunity against non-tuberculous mycobacteria. Front Immunol. 2019 Jun;26:10:1417.
14.
go back to reference Park TY, Chong S, Jung JW, et al. Natural course of the nodular bronchiectatic form of Mycobacterium Avium complex lung Disease: long-term radiologic change without treatment. PLoS ONE. 2017;12(10):e0185774.CrossRefPubMedPubMedCentral Park TY, Chong S, Jung JW, et al. Natural course of the nodular bronchiectatic form of Mycobacterium Avium complex lung Disease: long-term radiologic change without treatment. PLoS ONE. 2017;12(10):e0185774.CrossRefPubMedPubMedCentral
15.
go back to reference Deshmukh A, Vadala R, Talwar D. Utility of Bronchiectasis severity index (BSI) as prognostic tool in patients with post tubercular bronchiectasis: an experience from a tertiary care hospital in North India. Indian J Tuberc. 2021;68(2):261–5.CrossRefPubMed Deshmukh A, Vadala R, Talwar D. Utility of Bronchiectasis severity index (BSI) as prognostic tool in patients with post tubercular bronchiectasis: an experience from a tertiary care hospital in North India. Indian J Tuberc. 2021;68(2):261–5.CrossRefPubMed
16.
go back to reference Martinez-Garcia MA, Athanazio RA, Girón R, et al. Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. Int J Chron Obstruct Pulmon Dis. 2017;12:275–84.CrossRefPubMedPubMedCentral Martinez-Garcia MA, Athanazio RA, Girón R, et al. Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. Int J Chron Obstruct Pulmon Dis. 2017;12:275–84.CrossRefPubMedPubMedCentral
17.
go back to reference Jeong YJ, Lee KS, Koh WJ, Han J, Kim TS, Kwon OJ. Nontuberculous mycobacterial pulmonary Infection in immunocompetent patients: comparison of thin-section CT and histopathologic findings. Radiology. 2004;231(3):880–6.CrossRefPubMed Jeong YJ, Lee KS, Koh WJ, Han J, Kim TS, Kwon OJ. Nontuberculous mycobacterial pulmonary Infection in immunocompetent patients: comparison of thin-section CT and histopathologic findings. Radiology. 2004;231(3):880–6.CrossRefPubMed
18.
go back to reference Zhang ZX, Cherng BPZ, Sng LH, et al. Clinical and microbiological characteristics of non-tuberculous mycobacteria Diseases in Singapore with a focus on pulmonary Disease, 2012–2016. BMC Infect Dis. 2019;19(1):436.CrossRefPubMedPubMedCentral Zhang ZX, Cherng BPZ, Sng LH, et al. Clinical and microbiological characteristics of non-tuberculous mycobacteria Diseases in Singapore with a focus on pulmonary Disease, 2012–2016. BMC Infect Dis. 2019;19(1):436.CrossRefPubMedPubMedCentral
19.
20.
go back to reference Schweitzer MD, Salamo O, Campos M, et al. Body habitus in patients with and without bronchiectasis and non-tuberculous mycobacteria. PLoS ONE. 2017;12(9):e0185095.CrossRefPubMedPubMedCentral Schweitzer MD, Salamo O, Campos M, et al. Body habitus in patients with and without bronchiectasis and non-tuberculous mycobacteria. PLoS ONE. 2017;12(9):e0185095.CrossRefPubMedPubMedCentral
21.
go back to reference Georgakopoulou VE, Trakas N, Damaskos C, et al. Neutrophils to Lymphocyte Ratio as a Biomarker in Bronchiectasis Exacerbation: a retrospective study. Cureus. 2020;12(8):e9728.PubMedPubMedCentral Georgakopoulou VE, Trakas N, Damaskos C, et al. Neutrophils to Lymphocyte Ratio as a Biomarker in Bronchiectasis Exacerbation: a retrospective study. Cureus. 2020;12(8):e9728.PubMedPubMedCentral
22.
go back to reference Koseoglu S, Ozcan KM, Ikinciogullari A, et al. Relationship between neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and obstructive sleep apnea syndrome. Adv Clin Exp Med. 2015 Jul-Aug;24(4):623–7. Koseoglu S, Ozcan KM, Ikinciogullari A, et al. Relationship between neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and obstructive sleep apnea syndrome. Adv Clin Exp Med. 2015 Jul-Aug;24(4):623–7.
23.
go back to reference Curbelo J, Luquero Bueno S, Galván-Román JM, et al. Correction: inflammation biomarkers in blood as mortality predictors in community-acquired Pneumonia admitted patients: importance of comparison with neutrophil count percentage or neutrophil-lymphocyte ratio. PLoS ONE. 2019;14(2):e0212915.CrossRefPubMedPubMedCentral Curbelo J, Luquero Bueno S, Galván-Román JM, et al. Correction: inflammation biomarkers in blood as mortality predictors in community-acquired Pneumonia admitted patients: importance of comparison with neutrophil count percentage or neutrophil-lymphocyte ratio. PLoS ONE. 2019;14(2):e0212915.CrossRefPubMedPubMedCentral
24.
go back to reference Nacaroglu HT, Erdem SB, Karaman S et al. Can mean platelet volume and neutrophil-to-lymphocyte ratio. Be biomarkers of acute exacerbation of bronchiectasis in children? Cent Eur J Immunol. 2017;42(4):358–62. Nacaroglu HT, Erdem SB, Karaman S et al. Can mean platelet volume and neutrophil-to-lymphocyte ratio. Be biomarkers of acute exacerbation of bronchiectasis in children? Cent Eur J Immunol. 2017;42(4):358–62.
Metadata
Title
A case-control study on the risk factors associated with the occurrence of non-tuberculous mycobacteria pulmonary disease in bronchiectasis patients
Authors
Yinping Feng
Jing Guo
Shuirong Luo
Zunjing Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2023
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-023-02768-y

Other articles of this Issue 1/2023

BMC Pulmonary Medicine 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine